Safety and Efficacy of Lumiracoxib Versus Naproxen in Acute Musculoskeletal Pain
Phase 4
Completed
- Conditions
- Musculoskeletal Pain
- Registration Number
- NCT00170898
- Lead Sponsor
- Novartis
- Brief Summary
This study is designed to develop our understanding of the risk-benefit of using lumiracoxib in patients with acute musculoskeletal pain due to uncomplicated soft tissue injury.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 419
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Decrease in sum of pain intensity difference scores over first 5 days of treatment
- Secondary Outcome Measures
Name Time Method Decrease in sum of pain intensity difference scores over 7 days of treatment; Improvement in how pts feel about their pain; Comparable perceived pain relief; Comparable treatment satisfaction Safety and efficacy as compared to naproxen.
Trial Locations
- Locations (1)
For site information contact, Novartis Pharmaceuticals UK Limited
🇬🇧Frimley, United Kingdom